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Age-standardized incidence rates for PC ranged from 4.5 to 170.2 cases per 100,000 
males per year, and was 110.8 per 100,000 males per year in the EU. The annual per-
centage increase in PC ranged from 2.8% in Australia to 8.6% in China. The cost of 
PC management in Europe was highest in France (EUR 722 million). Key cost drivers 
were identified as the initial year of care, radical prostatectomy, and terminal care. 
Compared with other EU countries, higher use of radical prostatectomy and lower use 
of active surveillance in France result in a higher cost burden. ConClusions: The 
incidence of PC is increasing in the majority of countries with data available. The cost 
of illness is rising accordingly, and the cost differential between active surveillance 
and intervention is substantial. Selecting the optimal treatment per patient is likely 
to be an important aspect in limiting the increase in the PC burden.
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objeCtives: Bortezomib (BOR), lenalidomide (LEN), thalidomide (THAL) are avail-
able to patients with multiple myeloma (MM) in Japan, and new drugs are also to 
be launched. Introduction of Health Technology Assessment in FY2016 is aimed in 
Japan. The severity and its expensive treatment cost of MM disease may become 
important subjects to be discussed although a lack of resources for assessing cost-
effectiveness of treatment has been pointed out in Japan. The objective of this study 
was to sort epidemiological data and information on currently available treatments 
for MM through a systematic review and to estimate an expected total medical cost 
for relapsed/refractory MM (RRMM) patients. Methods: The literature search was 
conducted in MEDLINE and Ichushi-Web. Eligible studies were those of Japanese 
patients and published in the past 10 years. Studies were assessed for the followings: 
incidence and prevalence rate, number of patients, mortality rate, development rate 
of acute myelogenous leukemia (AML), and clinical effectiveness of current therapies. 
Expected total medical cost per RRMM patient was calculated from a model with 
overall survival and progression-free survival of RRMM patients based on literature 
review, assuming salvage therapies were comprised of BOR, LEN, and THAL. Results: 
Annual incidence and 5-year prevalence rates of MM were reported as 1.3 to 5.4 and 
9.7 per 100,000 persons, respectively. Although mortality rates were reported, data 
on AML development of MM patients tended to lack. Clinical trials of BOR and THAL-
based treatments were found, while there was only one for LEN-based treatment. 
An expected total medical cost for RRMM patient was estimated to be over € 100,000 
(1,383,000 yen). ConClusions: While the study indicated large medical resources 
usage of MM and the necessity of cost-effective evaluation for MM treatments, few 
studies have revealed its burden. Further studies on current situation surrounding 
MM treatments are expected.
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objeCtives: Gastrointestinal stromal tumors (GIST) are rare but costly tumors 
with an estimated incidence of 1.5/100 000/year in Europe. Granting reimburse-
ment requires locally adapted cost effectiveness data in Turkey. This study was con-
ducted to estimate the costs-of disease and direct cost components of metastatic/
inoperable GISTs that did not respond to prior imatinib mesylate and sunitinib 
malate. Methods: Bayer Turkey Market Access team organized an “expert panel” 
composed of oncologists to discuss the local treatments, routine monitoring and 
adverse event management algorithms in metastatic/inoperable GIST patients. The 
panel reviewed the global and local literature and guidelines and also discussed 
the spectrum of frequently performed local clinical practices. All cost components, 
including medications, hospitalization, out-patient follow-up procedures and reha-
bilitation services were reviewed. End of 2014 local prices for medications and pro-
cedures were used as sources. Based on the answers of the physicians, the cost of 
healthcare resources regarding the conditions described were calculated from the 
perspective of the Turkish payer (SSI – Social Security Institution). Results: In met-
astatic/inoperable GIST patients, treatment should be continued indefinitely, since 
treatment interruption is generally followed by relatively rapid tumor progression 
in almost all cases, even when lesions have been previously surgically excised. The 
cost of routine monitoring in the follow-up of metastatic/inoperable GIST patients 
was estimated to be 62.40 TL/month during progression-free and post-progression 
periods, while it was 490.00 TL/month during the terminal phase. The greatest cost 
is estimated for hospitalization in the intensive care unit ranging from 200.00 to 
800.55 TL per incident. The most common adverse reactions were listed as hand and 
foot skin reaction (4%) and diarrhea (6.7%). ConClusions: The costs of the disease, 
which therefore are quite high, estimated here will provide the most reliable data 
reflecting current figures to Public Stakeholders. Despite these high expenditures, 
those treatments’ efficacy is not clinically proven.
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objeCtives: To analyze the inpatients direct medical costs and reimbursement 
rate of breast cancer based on national claimed database for urban employees and 
compare on the cost of different types of treatment. Methods: Mechanical sam-
costs from a hospital centered view and four studies included costs from a third 
party payer view. Overall, the mean total treatment cost of pancreatic cancer treat-
ment ranged from € 8,037 to € 38,232 per patient. The cost of resectable disease ranged 
from € 19,890 to € 120,071 per patient. The cost of unresectable disease ranged from 
€ 14,899 to € 58,208. The cost of metastatic disease ranged from € 13,873 to € 43,679. 
The cost of laparoscopic distal pancreatectomy ranged from € 9,603 per patient to 
€ 15,433 per patient. The cost of open distal pancreatectomy ranged from € 10,944 per 
patient to € 22,790 per patient. 15 studies reported cost-effectiveness data. The incre-
mental cost-effectiveness ratio (ICER) of folfirinox compared to gemcitabine ranged 
from € 48,637 per quality adjusted life years (QALY) to € 62,657 per QALY. The ICER of 
surgery followed by chemotherapy compared to surgery alone ranged from € 34,636/
QALY to € 81,971/QALY. ConClusions: Surgery is an important cost-driving factor in 
pancreatic cancer treatment. Wide variations in cost are reported, probably reflecting 
the variation in health care systems.
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Dasika G, Pennington B, Nielsen SK
BresMed, Panaji, India
objeCtives: A 2014 study by Bhaskaran et al. found that an increase in BMI was asso-
ciated with an increased risk of cancer in 10 sites. The National Health Service (NHS) 
England cancer related expenditure for the cancers in these 10 sites from Bhaskaran 
et al. accounted for £2.78 billion in 2012/13. This study estimated the increasing cost 
burden of these cancers to NHS England relative to increasing BMI. Methods: The 
analysis used the primary care trust (PCT) expenditure for the financial year 2012/13 
of NHS England. The 10 cancers found by Bhaskaran et al. whose incidences increase 
as BMI increases were linked to the ‘cancers and tumours’ category of the cancer 
expenditure. We calculated the cancer expenditure attributable to obesity for each of 
the 10 cancers using risks reported by Bhaskaran et al. Bhaskaran et al. also reported 
hazard ratios (HRs) for incidence of each cancer for a 5kg/m2 increase in BMI – we 
used these HRs to estimate the increased cost of each of the 10 cancers for increase 
in population BMI. Results: We calculated that the 2012/13 cost burden of the 10 
cancers attributable to obesity was £0.32 billion. If the mean population-wide BMI 
increased by 5 kg/m2 we estimated that the cost burden of 10 cancers attributable to 
obesity would have increased to £0.41 billion from £0.32 billion in 2012/13. The cost 
burden would increase most dramatically for uterus cancer, with a predicted increase 
of 62%. ConClusions: Cancers attributable to obesity have a high cost burden. A 
population-wide increase in BMI would result in higher incidence of 10 cancers. The 
cost to NHS England would increase dramatically, with the required budget increasing 
by more than 25% for an increase in BMI of 5kg/m2.
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objeCtives: To summarize the existing literature regarding the medical cost associ-
ated with treatment and follow-up of head and neck cancer. Methods: PubMed 
was used as search engine to retrieve publications in Medline using the search term 
“(head and neck cancer) AND (cost)” with a publication date filter (from January 1st 
2000 up to September 1st 2014) and language filter (English). This search yielded 
2,635 publications of which 97 were relevant for this review. Cost were recalculated 
in Euros (€ ) using the June 5 2015 currency rate of $1 = € 0.8914. Results: In six stud-
ies total treatment cost from diagnosis to discharge ranged from € 15,214 per patient 
to € 21,665 per patient. In four studies total medical cost including treatment and 
follow-up ranged from € 29,434 per patient to € 76,277 per patient. The reconstruction 
cost ranged from € 8,797 per patient to € 48,115 per patient. In three studies the cost 
of surgery performed by a high-volume surgeon ranged from € 7,869 per patient to 
€ 24,233 per patient and by a low-volume surgeon ranged from € 9,146 per patient to 
€ 22,067 per patient. In two studies the median cost for stage I disease ranged from 
€ 3,264 per patient to € 11,205 per patient, for stage II disease ranged from € 5,230 per 
patient to € 20,473 per patient, for stage III disease ranged from € 9,196 per patient 
to € 28,429 per patient and for stage IV disease ranged from € 10,222 per patient to 
€ 45,373 per patient. In three studies the Incremental Cost effectiveness Ration (ICER) 
of cetuximab plus radiotherapy compared to radiotherapy alone ranged from € 7,530 
per QALY to € 14,624 per QALY. ConClusions: The literature on the costs associated 
with the treatment of head and neck cancer is extensive. Wide variations in cost are 
reported, probably reflecting the variation in health care systems.
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objeCtives: Screening programs have resulted in prostate cancer (PC) diagnoses 
increasing and being made both earlier in the disease state and the patient’s life. 
Understanding the clinical and cost burden of PC and its associated treatment options 
is imperative for optimization of healthcare resources. Methods: A structured lit-
erature review of three publication databases (PubMed, EMBASE, and the Cochrane 
Library) was undertaken. Literature review was focused on publications with a major 
focus on “Prostatic Neoplasms” or containing the term “Prostate Cancer”. Secondary 
search criteria restricted results to contain information on epidemiology, cost of ill-
ness, adverse events, or treatment protocols. To ensure that recent estimates and 
practice guidelines were evaluated, literature was restricted to those published on 
or after January 1, 2009. Abstract screening selected publications reporting data from 
European countries and other nations with developed healthcare systems. Results: 
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of cost and resource use for both squamous and non-squamous management are 
substantial, especially considering the limited efficacy and high toxicity of existing 
treatments. Cost effectiveness of real-world treatment needs to be further explored.
PCN118
trEatmENt SEquENCiNg PattErNS aNd CoStS of CarE iN PatiENtS with 
rElaPSEd/rEfraCtory multiPlE myEloma
Potluri R1, Farr AM2, Hirji I3, Davis C4, Bhandari H5, Oukessou A4
1SmartAnalyst Inc., New York, NY, USA, 2Truven Health Analytics, Bethesda, MD, USA, 3Bristol-
Myers Squibb, Wallingford, CT, USA, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5SmartAnalyst 
India (Pvt.) Ltd., Gurgaon, India
objeCtives: To evaluate treatment sequences and associated costs among 
patients with relapsed/refractory multiple myeloma (RRMM). Methods: Patients 
with RRMM between January 2007 and September 2013 were identified from US 
MarketScan databases. Outcomes included treatment regimen per line (L; 2–4L), 
sequences of treatment regimens, and cost per line and of progression (2L vs > 2L). 
All-cause and MM-specific monthly costs captured inpatient, outpatient, emergency 
department, and drug-related costs, adjusted for censoring. Results: 4449 MM 
patients initiated a 2L regimen, of whom 38% (n= 1696) progressed to 3L and 15% 
(n= 689) progressed to 4L. Median follow-up was 14 months (range 1–83). The most 
frequent 2L regimens were lenalidomide (18%), lenalidomide-dexamethasone (12%), 
bortezomib-dexamethasone (12%), bortezomib-lenalidomide-dexamethasone (10%), 
and bortezomib (7%). Of patients whose prior therapy included an immunomodula-
tory drug (IMiD) (n= 1752), bortezomib-dexamethasone was the most common 2L 
regimen (17%); for those with no prior IMiD exposure (n= 2697), lenalidomide was 
the most common 2L (23%). Median time to start of 3L was 5.8 months. Among the 
27% of lenalidomide 2L patients who progressed to 3L, 64% had bortezomib-based 
regimens in 3L. Among the 47% of bortezomib-dexamethasone 2L patients who 
progressed to 3L, 63% had lenalidomide-based regimens in 3L. MM-specific costs 
were highest for all patients during the first year of 2L: $122,960 versus $74,573 
(12–24 mths), $68,940 (24–36 mths), $59,327 (36+ mths). Drug-related costs accounted 
for 39–62%, and were dependent on regimen and treatment line. During 0–36 mths, 
MM-specific costs after progression from 2L were higher by $122,823 compared 
with costs incurred on 2L. ConClusions: In this study of RRMM patients, 38% pro-
gressed to subsequent treatment lines, with variability in 2L regimens and treatment 
sequences. Highest costs were incurred during the first 12 months of follow-up. The 
cost of managing progressive disease in RRMM is high, as observed by the difference 
in costs before and after progression.
PCN119
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aggrESSivE hiStologiCal tyPES of NoN-hodgkiN lymPhomaS iN thE 
Slovak rEPuBliC. rESultS from thE CroSS-SECtioNal SurvEy iN thE 
haEmatology-oNCologiCal CENtErS
Ondrusova M1, Psenkova M1, Suchansky M1, Vranovsky A2, Chudej J3, Wild A4
1Pharm-In Ltd, Bratislava, Slovak Republic, 2National Cancer Institute, Bratislava, Slovak 
Republic, 3University hospital Martin, Martin, Slovak Republic, 4University Hospital F. D. Roosvelt, 
Banska Bystrica, Slovak Republic
objeCtives: The objective of this cross-sectional survey was to measure the 
resource utilisation and costs associated with health-care management of patients 
with aggressive histological types of Non-hodgkin lymphomas (a-NHLs) in Slovakia 
and to provide a basis for cost-effectiveness evaluations. The latest official national 
data on epidemiology of all NHLs are available for year 2008, prediction to 2015 
indicates the age-standardized (ASR-W) incidence to be 4.9/100,000 (n= 446 cases), 
from that DLBCL is estimated to be 311 cases (3.1/100,000). Overall point prevalence 
of all NHLs is estimated to 1,404 patients. Methods:: Descriptive data of 1,080 
a-NHLs patients from 3 biggest NHLs-centers from whole Slovakia were collected 
and analyzed. All types of health-care services, treatment management and costs 
were analyzed. Continuous variables were calculated using standard descriptive 
statistics methods. Results: 98.97% of patients were treated by the 1st line (L), out 
of them 97.10% of patients (95%CI:97.01%-97.19%) by rituximab. Proportion of remis-
sions after 1stL represented 63.47%, deaths 6.76% and progression/relaps 29.77% 
(95%CI:29,18%-30,36%), out of them 91.99% (95%CI:91.49%-92.50%) received 2ndL 
therapy. Proportion of remissions after 2ndL was 26.48%, deaths 11.27% and pro-
gression/relaps 62.25% (95%CI:62.16%-62.34%), out of them 91.04% (95%CI:90.42%-
91.66%) received 3rdL treatment. Proportion of remissions after 3rdL represented 
7.86%, deaths 35.68%, progression/relaps 57.61% (95%CI:56.99%-58.23%), out of them 
20.45% of patients (95%CI:18.50%-22.41%) are re-treated with rituximab. Overall 
costs of patient on active treatment during therapy represented € 1,609.80/28 days 
(95%CI: € 1,571.39-€ 1,648.72), in the post-treatment time € 31.56 (95%CI:€ 29.16-€ 34.10). 
Costs of palliative care represented € 1,283.53/28 days (95%CI:€ 1,197.88-€ 1,372.94) 
and one-off costs € 405.56 (95%CI:€ 400.88-€ 410.26). Costs of adverse events man-
agement ranged in the grade 2 from € 10.58/pain (95%CI:€ 8.50-€ 11.06) to € 103.23/
fatigue (95%CI:€ 100.01-€ 106.49); in the grade 3/4 from € 111.75/lymphopenia 
(95%CI:€ 105.78-€ 117.73) to € 4,518.06/other malignant tumors (95%CI:€ 4,476.87-€ 
4,559.26). ConClusions: Results of this cross-sectional survey determined the 
treatment strategies and average direct cost per a-NHL patient and can be used for 
the purposes of pharmaco-economic evaluations.
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objeCtives: Recent data characterizing metastatic SCCHN treatment pat-
terns in the UK are limited. The current study evaluated patterns of care and 
HCRU in UK patients with metastatic SCCHN who received ≥ 3 lines of systemic 
pling was used to collect data on inpatients costs of breast cancer in 3 cities (Beijing, 
Shanghai and Chengdu) in China in 2011. 314 patients were screened into this study 
from national claimed database of urban employees. Statistics analysis and descrip-
tive analysis were used to find out direct medical costs and reimbursement rate 
of patients hospitalized with breast cancer in different treatment type. Results: 
The mean hospitalization expense of all inpatient with breast cancer was USD 2,154 
per patient (66% of the expense was covered by public payer), while drug expense 
was USD 1,197 (82% covered by public payer). The mean cost per patient was CNY 
19,554 (USD 3,154) for surgery patients (49 patients) and CNY 10,588 (USD 1,708) for 
non-surgery patients (265 patients), the mean reimbursement rate was 60% and 
70%, drug-to-total expense ratio was 41% and 69% and mean length of hospital stay 
was 20 days and 9 days for surgery patients and non-surgery patients identically. 
The overall reimbursement rate of medical services was only 46%, much lower 
comparing with reimbursement rate of drug (82%), causing even higher OOP burden 
of surgery patients who usually needs more medical services (mean expense on 
medical services per surgery patient and non surgery patient was USD 1,875 and 
USD 536). ConClusions: Among women in China, breast cancer is the most com-
mon and the leading cause of death from all cancers, which brings heavy burden 
to patients and families. Surgery patients suffered higher OOP burden because of 
relatively lower reimbursement rate on medical services and longer hospital stay. 
The government needs to gradually raise the reimbursement rate and introduce 
more commercial health insurance products to cover on patient financial burden.
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hEalth aNd ECoNomiC BurdEN of BrEaSt CaNCEr mortality iN 
youNgEr womEN agEd 18-44 yEarS iN thE uNitEd StatES, 1970-2012
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objeCtives: Breast cancer is the second leading cause of cancer-related deaths 
among women age < 50 years. Published studies on the health and productivity 
effects of breast cancer mortality among younger women are limited. PuRPose: 
To assess trends in breast cancer mortality rates among young women aged 18-44 
years, estimate years of potential life lost (YPLL), and the value of productivity losses 
due to premature mortality. Methods: Age-adjusted rates and rate ratios (RRs) 
were calculated using 1970-2012 U.S. mortality data. Changes in breast cancer mor-
tality rates over time were assessed using Joinpoint regression modeling. YPLL was 
calculated using number of cancer deaths and the remaining life expectancy at the 
age of death. Value of productivity losses was estimated using the number of deaths 
and the present value of future lifetime earnings. Results: From 1970 through 
2012, the age-adjusted breast cancer mortality rate among young women was 
12.02/100,000. Rates were higher in the Northeast (RR = 1.03; 95% CI, 1.02-1.04). The 
annual decline in breast cancer mortality rates among blacks was smaller (-0.68%) 
compared with whites (-2.02%) and all race/ethnicity (-1.77%). The total number of 
deaths associated with breast cancer was 225,866, which accounted for an estimated 
7.98 million YPLL. The estimated total productivity loss in 2008 was $5.49 billion 
and individual lifetime lost earnings were $1.10 million. ConClusions: Breast 
cancer mortality among young women is associated with substantial health and 
economic burden. Considering the effect of breast cancer on women of working-age 
and the disproportionate impact on black women, more aggressive interventions 
with multiple strategies are needed to help reduce these burdens, improve survival 
and in turn reduce productivity costs associated with premature death.
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objeCtives: Across Europe, clinical and economic burden of advanced non-small 
cell lung cancer (aNSCLC) remains high; regional variation and cost drivers are 
not completely understood. The Leading the Evaluation of Non-squamous and 
Squamous NSCLC (LENS) study aimed to systematically describe aNSCLC-attrib-
utable healthcare resource utilization (HCRU) and costs within aNSCLC patients 
who received ≥ 2 lines of systemic therapy. Methods: Patients diagnosed with 
aNSCLC (Stage IIIb/IV) between 07/2009-08/2011 who initiated second-line treat-
ment (excluding clinical trial patients) were quota sampled from 153 oncology/
pulmonology practices (92% hospital-based) in France, Germany, Italy, and Spain. 
Medical charts were reviewed for patient characteristics and outcomes including 
aNSCLC-related HCRU from diagnosis through death or most recent visit (data 
abstracted in January-May 2014). Country-specific unit costs were obtained from 
national price indexes and published literature, inflated to 2014€ . Average lifetime 
costs were calculated using observed and Kaplan-Meier approaches to adjust for 
incomplete follow-up. Results: 835 patients (Non-squamous= 418, Squamous= 417; 
France= 191, Germany= 225, Italy= 220, Spain= 199; median age 65 years; 85.0% smok-
ing history; 39.8% current smokers) were observed over a mean 20.7 months (range 
2.8-57.1 months; 76.3% followed through death). 11.9%/6.1% had aNSCLC-related 
hospitalizations/ER visits, 68.3% biomarker testing, 16.8% radiotherapy, 4.2% sur-
gery, and 27.9% supplemental therapies. Estimated per-patient lifetime aNSCLC-
attributable costs were € 62,481 (France= € 54,936, Germany= € 71,508, Italy= € 41,447, 
Spain= € 65,424). Costs were driven by systemic treatment (systemic treatment 
cost= € 50,737; in squamous, € 28,107; non-squamous, € 71,060). ConClusions: 
Treatment was the primary aNSCLC-related cost driver, with histology-based dif-
ferences driven by lower systemic use in squamous patients. The observed levels 
